



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

Date: July 21, 2021 **Time:** 10:00am – 3:00pm (CST) **Location:** Webex

[Join Webex Meeting](#)

Meeting number (access code): 177 246 4804

Meeting password: p7Njt3CDMm9

Join From a Video System/Application

Dial [1772464804@stateofmo.webex.com](tel:1772464804)

Or dial 173.243.2.68 and enter the meeting number

Join From a Mobile Device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
---------------	--	------------

Clinical and Fiscal Edit Review

11:00 – 11:45	<u>Existing Criteria</u> <ul style="list-style-type: none">i. Ampyraii. Elagolixiii. Gamifantiv. Koselugov. Luxturnavi. Oxervatevii. Reblozylviii. Synagisix. Tepezzax. Tolvaptanxi. Zometa <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none">i. CAR-T Cellii. Crysvida	Josh Moore
---------------	--	------------

- iii. Duchenne Muscular Dystrophy
- iv. Entresto
- v. Extended Supply - *NEW*
- vi. HBV Nucleotide Analog - *NEW*
- vii. Imcivree - *NEW*
- viii. Iron, Injectable
- ix. Nulibry - *NEW*
- x. Oxazolidinone - *NEW*
- xi. Palynziq
- xii. PTH Agents
- xiii. Verquvo - *NEW*
- xiv. Zokinvy - *NEW*

Preferred Drug List Edit Review

11:45 – 1:00

Existing Criteria

Josh Moore

- i. Amylin Analogs
- ii. Antibiotics, Vaginal
- iii. Bile Salt Agents
- iv. Cephalosporin Agents
- v. Electrolyte Depleting Agents, Phosphate Lowering
- vi. Electrolyte Depleting Agents, Potassium Lowering
- vii. Fluoroquinolone Agents, Oral
- viii. Insulin, Mixed
- ix. Insulin, Non-Analogs
- x. Penicillin Agents
- xi. Sulfonylureas, Second Generation
- xii. Targeted Immune Modulators, IL6 Receptor Inhibitors
- xiii. Thrombocytopenia Agents

New Criteria or Revision of Existing Criteria

- i. Alpha-Glucosidase Inhibitors
- ii. Antibiotics, GI Oral
- iii. Antibiotics, Mupirocin Topical – *NEW*
- iv. Antihyperuricemic Agents
- v. Benign Prostatic Hyperplasia (BPH) Agents
- vi. Biguanides & Combinations
- vii. Bone Ossification Agents
- viii. Colony Stimulating Factors
- ix. Cryopyrin-Associated Periodic Syndrome Agents
- x. DPP-IV Inhibitors & Combinations
- xi. Erythropoiesis Stimulating Agents
- xii. GLP-1 Receptor Agonists & Combinations
- xiii. Growth Hormone Agents, Somatropin
- xiv. Growth Hormone & Growth Hormone Releasing Factors, Select Agents
- xv. Insulin, Long Acting
- xvi. Insulin, Rapid Acting
- xvii. LHRH/GnRH Agents, Non-Oral – *NEW*
- xviii. Macrolides
- xix. Meglitinides
- xx. Methotrexate Agents
- xxi. Multiple Sclerosis Agents, Injectable
- xxii. Multiple Sclerosis Agents, Oral
- xxiii. SGLT2 Inhibitors & Combinations

- xxiv. Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists
- xxv. Targeted Immune Modulators, IL23 Inhibitors & IL23/IL12 Inhibitors
- xxvi. Targeted Immune Modulators, JAK Inhibitors
- xxvii. Targeted Immune Modulators, Select Agents
- xxviii. Targeted Immune Modulators, TNF Inhibitors
- xxix. Tetracycline Agents
- xxx. Thiazolidinediones & Combinations
- xxxi. Urinary Tract Antispasmodics

Break

1:00 – 1:15 Lunch

Program Utilization Information – Conduent Update

1:15 – 1:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

1:30 – 2:00 Other Business

Executive Session

2:00 – 3:00 Patient Profile Reviews

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

NEXT MEETING: October 20, 2021

***Beginning July 2021, unless otherwise notified, the Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) meetings will allow in-person attendance for only board members and associated MO HealthNet staff. Webex will still be available for all other attendees.**

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*